Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics

• ClinicalTrials.gov Identifier: NCT00252291
• Recruitment Status: Completed
• First Posted: November 11, 2005
• Last Update Posted: December 1, 2009
• Sponsor: Pharmaxis
• Information provided by: Pharmaxis

Study Description

Brief Summary:

This is a Phase 3 study to determine the sensitivity and specificity of the Aridol bronchial challenge test to detect bronchial hyperresponsiveness in patients with suspected asthma. Patients with suspected asthma of either gender, aged between 6 and 50 years, with only mildly impaired lung function (FEV1 >70%) are to be tested with three different bronchial hyperresponsiveness challenges (Aridol, exercise and methacholine), and the results compared. A clinical diagnosis will also be made at the end of the study.

Condition or disease	Intervention/treatment	Phase
Asthma	Drug: Aridol; Drug: Methacholine; Procedure: Exercise challenge	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Enrollment: 240 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Single
• Primary Purpose: Diagnostic
• Official Title: A Phase III Multicenter Study to Demonstrate the Sensitivity and Specificity of Aridol (Mannitol) Challenge to Predict Bronchial Hyperresponsiveness as Manifested by a Positive Exercise Challenge in Subjects Presenting With Signs and Symptoms Suggestive of Asthma But Without a Definitive Diagnosis
• Study Start Date: November 2005
• Actual Study Completion Date: September 2006

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

1. Comparison of Aridol and exercise BHR tests
2. Safety of Aridol test

Secondary Outcome Measures :

1. Comparison of Aridol and methacholine test
2. Comparison of Aridol test and clinical diagnosis

Eligibility Criteria

• Ages Eligible for Study: 6 Years to 50 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Have given informed consent to participate in this study in accordance with local regulations prior to any procedures being performed
2. Have signs and symptoms suggestive of asthma according to the NIH Questionnaire but has not been given a firm diagnosis of asthma or a firm exclusion of the diagnosis of asthma (e.g. has an equivocal diagnosis of asthma or been referred for further investigation of asthma type symptoms)
3. Have at least Step 1 symptoms according to the NAEPPII asthma severity grading
4. Have an FEV1 ≥ 70% of the predicted value at Screening Visit (Visit 1) baseline
5. Be between 6 and 50 years
6. Be able to perform all of the techniques necessary to measure lung function including an exercise challenge, Aridol challenge and methacholine challenge
7. Be able to understand the requirements of the study and be able to complete all of the forms necessary including the NIH Questionnaire
8. Be taking effective birth control if female of childbearing potential

Exclusion Criteria:

1. Use medications six weeks prior to the Screening Visit (Visit 1) or during the study that would interfere with bronchial provocation challenge testing (see Table 1, section 3.3.3.4)
2. Currently use cholinesterase-inhibitor medication (for myasthenia gravis)
3. Have had upper or lower respiratory tract infection within the previous 4 weeks
4. Have known aortic or cerebral aneurysm, cirrhosis or portal hypertension
5. Have had recent major surgery
6. Have had recent cataract surgery
7. Have a history of heart disease that would increase risk of performing exercise, methacholine or Aridol challenge
8. Have had cardiac ischemia or malignant arrhythmias
9. Have uncontrolled hypertension (systolic blood pressure ≥ 180 and diastolic blood pressure ≥ 100)
10. Have orthopedic limitations
11. Have smoked within the past year (average > 1 cigarette per week), or have a ≥ 10 pack year smoking history
12. Have other chronic restrictive or obstructive pulmonary diseases (cystic fibrosis, COPD, bronchiectasis, chronic bronchitis, emphysema, tuberculosis, pulmonary carcinoma, pulmonary fibrosis, pulmonary hypertension, hypercapnia)
13. Be skin test positive to seasonal and perennial aeroallergens that are present in the environment during the time that the subject is enrolled in the study, or if skin test positive to these aeroallergens the subject must not report worsening of symptoms when exposed to these aeroallergens during the time that the subject is participating in the study
14. Have a medical condition that in the opinion of the Investigator would impair the ability of the subject to participate
15. Have an inability to perform spirometry of acceptable quality
16. Be intolerant to Aridol, methacholine or albuterol
17. Be pregnant or lactating
18. Have participated in any other investigative drug study parallel to, or within 4 weeks of study entry
19. Be an Investigator, site employee or otherwise be directly affiliated with the study site including being a member of the immediate family of an Investigator, site employee (where an immediate family member is defined as spouse, parent, child or sibling, whether biological or legally adopted or in foster care)
20. Have a body mass index (BMI) ≥ 30
21. Have been diagnosed at Screening Visit (Visit 1) as definitively having or not having asthma; patients that will not continue in the study include those given the following diagnosis: asthma is extremely likely or definite (95 to 100% likelihood) or asthma is very unlikely or excluded (0 to < 5% likelihood)
22. Have previously been enrolled in this study at this or at any other clinical trials site
23. Have previously received an Aridol challenge
24. Have a clinically significantly abnormal chest x-ray

Contacts and Locations

Locations

United States, Colorado

Colorado Asthma and Allergy Centers, 125 Rampart Way

Denver, Colorado, United States, 80230-6405

Sponsors and Collaborators

Pharmaxis

Investigators

• Principal Investigator: David Pearlman, MD; Colorado Asthma and Allergy Centers, Denver, CO

More Information

Publications:

Anderson SD, Brannan J, Spring J, Spalding N, Rodwell LT, Chan K, Gonda I, Walsh A, Clark AR. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):758-65. doi: 10.1164/ajrccm.156.3.9701113.

Subbarao P, Brannan JD, Ho B, Anderson SD, Chan HK, Coates AL. Inhaled mannitol identifies methacholine-responsive children with active asthma. Pediatr Pulmonol. 2000 Apr;29(4):291-8. doi: 10.1002/(sici)1099-0496(200004)29:43.0.co;2-a.

Holzer K, Anderson SD, Chan HK, Douglass J. Mannitol as a challenge test to identify exercise-induced bronchoconstriction in elite athletes. Am J Respir Crit Care Med. 2003 Feb 15;167(4):534-7. doi: 10.1164/rccm.200208-916OC. Epub 2002 Nov 27.

Koskela HO, Hyvarinen L, Brannan JD, Chan HK, Anderson SD. Sensitivity and validity of three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in asthma. Chest. 2003 Oct;124(4):1341-9. doi: 10.1378/chest.124.4.1341.

• ClinicalTrials.gov Identifier: NCT00252291
• Other Study ID Numbers: DPM-A-305
• First Posted: November 11, 2005
• Last Update Posted: December 1, 2009
• Last Verified: November 2009

Keywords provided by Pharmaxis:

bronchial; hyperresponsiveness

Additional relevant MeSH terms:

Asthma; Bronchial Hyperreactivity; Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Methacholine Chloride; Miotics; Autonomic Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Parasympathomimetics; Bronchoconstrictor Agents; Respiratory System Agents; Muscarinic Agonists; Cholinergic Agonists; Cholinergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action